Kwality Pharmaceuticals Ltd Company Summary

Kwality Pharmaceuticals Limited was Incorporated on May 4th 1983 when its founder Mr. Ramesh Arora was inspired to begin his own venture leaving behind the already flourishing family business of spinning and aromatics. With little background of finished pharmaceuticals and high held spirits and will, he started this business.

He received his first drug license in 1981 approved for liquid oral manufacturing. Presently, the Company has 65 different sections available at their production centres.Kwality Pharmaceuticals Ltd. are manufacturer of finished pharmaceutical formulations in a Liquid Orals, Dry Syrups, Tablets, Capsules, Sterile Powder for Injections and small volume injectables.

Apart from these, the Company is making medicines in various dosage forms like Liquid Orals, Powder for Oral Suspension, Tablets, Capsules, Dry Syrup, Syrup, Sterile Powder for Injections, small volume injectables, Ointments, External Preparations, ORS and many more in various categories like Beta Lactam & non-Beta Lactam, Hormones, Cytotoxic (Oncology) and Effervescent as per new GMP norms. Besides, it manufacture the latest drugs for the management of viral infections/diseases in different dosage forms. The Company had put up a multi-storied factory building in Nag Kalan, Amritsar, which started its production in March 2006.

The new factory was as per WHO GMP norms. It put up the Jassur Plant in Himachal Pradesh. This unit was in the TAX-free zone, which has helped the Company to sell its Products into the Indian retail market.

Kwality Pharmaceuticals, as an exporting company has supplied Remdesivir Injection to the global market and similarly Propofol injection was short in supply in various high profile countries who normally accept US FDA companies products. But in shortage of medicine, they procured these injections from the Company and after seeing the performance and efficacy, they registered the product. With approvals from leading global regulatory bodies such as EU-GMP, SFDA, INVIMA, ANVISA, among others, the Company expanded the footprint to 80 countries in FY 2026.